G1 Therapeutics

G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer. G1’s two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, which represent a validated and promising target for anticancer therapy. Trilaciclib and G1T38 have broad therapeutic potential across multiple forms of cancer and can serve as the backbone of various combination regimens. Additionally, G1 is advancing G1T48, a potential first-in-class/best-in-class oral selective estrogen receptor degrader, or SERD, which is intended to treat ER+ breast cancer.